AngioDynamics (ANGO) has a market capitalization of approximately $580M, trading at
AngioDynamics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
AngioDynamics runs a net profit margin of -11.5%, a gross margin of 54.6%, and an operating margin of -12.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
AngioDynamics reported revenue of
AngioDynamics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
AngioDynamics carries a debt-to-equity ratio of 0.00x and a current ratio of 2.19x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For AngioDynamics (ANGO) the key facts are: market cap $580M, revenue
Get AngioDynamics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.